2017 Press Releases

Webcast ImageWebcast
Q3 2017 T2 Biosystems Inc. Earnings Conference Call (Live)
11/02/17 at 4:30 p.m. ET
Q3 2017 T2 Biosystems Inc. Earnings Conference Call
Thursday, November 2, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
10/16/17T2 Biosystems Announces 2017 Third Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, MA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that it will release its 2017 third quarter financial and operational results after the market closes on Thursday, November 2, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Thursday, November 2, 2017, to disc... 
Printer Friendly Version
10/12/17Clinicians Discuss Positive Impact of T2MR Platform on Sepsis Care at IDWeek 2017
Clinicians present clinical and economic value of the T2Sepsis Solution and discuss potential of T2Bacteria Panel LEXINGTON, Mass., Oct. 12, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced new data presented during the IDWeek 2017 Conference on the T2Sepsis SolutionTM, which includes the T2Bacteria® Panel, commercially available in Europe today and recently submitted ... 
Printer Friendly Version
10/03/17Study Published in Journal of Antimicrobial Stewardship Shows Patients Diagnosed with T2Candida Panel Treated More Than Eight Times Faster
T2MR platform shown to lead to appropriate therapy in 5 hours compared to 44 hours based on blood culture LEXINGTON, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that Henry Ford Health System published the clinical impact of the T2Candida Panel in The Journal of Antimicrobial Stewardship. The study, titled “T2 Magnetic Resonance Assay Improves Timel... 
Printer Friendly Version
09/21/17T2 Biosystems Announces Presentations at IDWeek 2017
LEXINGTON, MA, September 21, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced a panel presentation and six poster presentations during the IDWeek 2017 Conference in San Diego, CA, held October 4-8. The panel presentation will be focused on the positive impact of the T2Candida Panel, early experiences with the T2Bacteria Research Use Only (RUO) Panel and how the deve... 
Printer Friendly Version
09/18/17T2 Biosystems to Present at the Cantor Fitzgerald Global Healthcare Conference
LEXINGTON, Mass., Sept. 18, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, and Darlene Deptula-Hicks, SVP and chief financial officer, are scheduled to attend and present at the Cantor Fitzgerald Global Healthcare Conference. The conference is being held September 25-27, 2017 at the InterContinental New York ... 
Printer Friendly Version
09/15/17T2 Biosystems Announces Pricing of Public Offering of Common Stock
LEXINGTON, Mass., Sept. 15, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced the pricing of an underwritten registered public offering of 4,375,000 shares of common stock at a public offering price of $4.00 per share, before underwriting discounts, for gross proceeds of $17,500,000. T2 Biosystems has granted the underwriters a 30-day option to purchase up to an additional 656,250 shares of common stock at the public offering price, less the underwriting discount.  All... 
Printer Friendly Version
09/14/17T2 Biosystems Announces Proposed Public Offering of Common Stock
LEXINGTON, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it is commencing an underwritten registered public offering of shares of its common stock. T2 Biosystems also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock sold in the offering.  All of the shares are being offered by T2 Biosystems. The offering is subject to market conditions, and there can be no assuran... 
Printer Friendly Version
09/11/17T2 Biosystems Submits 510(k) Application to the FDA for Review of T2Bacteria Panel
T2Bacteria Panel pivotal clinical trial demonstrates highly accurate results with overall average sensitivity of 95.8% and average specificity of 98.1% LEXINGTON, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that it has filed a 510(k) premarket submission for the T2Bacteria Panel with the U.S. Food and Drug Administration (FDA). The T2Bacteria Pane... 
Printer Friendly Version
09/06/17T2 Biosystems and Cidara Therapeutics Announce Partnership for Commercial Placement of T2Dx Instruments to Support CD101 Drug Trials
Exclusive pricing program designed to drive uptake of T2 Biosystems’ products and accelerate enrollment in Cidara’s CD101 trials, targeting deadly sepsis-causing pathogen Candida LEXINGTON, Mass. and SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, and Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immun... 
Printer Friendly Version
09/06/17T2 Biosystems Announces Collaboration with CDC to Detect Emerging Superbug Candida auris
CDC to Utilize T2Dx Instrument for Testing of Patient Samples and Monitoring Hospital Environments New Application of T2MR Technology for Detection of Candida auris in Patient Skin, Patient Blood and Hospital Environmental Samples Now Available for Investigational Purposes LEXINGTON, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that the Centers ... 
Printer Friendly Version
08/30/17T2 Biosystems Announces 11 New Patents Granted in 2017
Advances T2 Biosystems’ technological advantage for T2MR platform LEXINGTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today that it has been granted 11 new patents in 2017 that further broaden and strengthen the protection around the company’s proprietary T2 Magnetic Resonance (T2MR) platform, including the T2Sepsis Solution and hemostasis technology.... 
Printer Friendly Version
08/03/17T2 Biosystems Reports Second Quarter 2017 Financial Results; Provides Company Update
Sequential Quarterly Product Revenue Growth of 16.5% LEXINGTON, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today operating highlights and financial results for the second quarter ended June 30, 2017.    Second Quarter Business and Financial Performance Highlights: Second quarter product revenue was $735,000, a $584,000 increase from the second q... 
Printer Friendly Version
08/02/17T2 Biosystems to Present at the 37th Annual Canaccord Genuity Growth Conference
LEXINGTON, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, and Darlene Deptula-Hicks, SVP and chief financial officer, are scheduled to attend and present at the 37th Annual Canaccord Genuity Growth Conference. The conference is being held August 9-10, 2017 at the InterContinental Hotel in Bosto... 
Printer Friendly Version
07/27/17T2 Biosystems Joins Antimicrobials Working Group as First Diagnostic Member
LEXINGTON, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today that it will join the Antimicrobials Working Group (AWG) as its first diagnostic member. T2 Biosystems joins thirteen antimicrobials companies in their mission to combat drug resistant infections and spur life-saving innovations.   “Diagnostics play a vital role in providing the best possible... 
Printer Friendly Version
07/20/17T2 Biosystems Announces 2017 Second Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., July 20, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that it will release its 2017 second quarter financial and operational results after the market closes on Thursday, August 3, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Thursday, August 3, 2017, to disc... 
Printer Friendly Version
07/18/17T2 Biosystems Receives CE Mark for T2Bacteria™ Panel Enabling Commercialization in Europe
New Diagnostic Test Panel Expands Platform Menu Providing Comprehensive T2Sepsis Solution™ for Hospitals LEXINGTON, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today that it has received a CE Mark for its T2Bacteria Panel, allowing for the sale and distribution of the product within the European Union and those countries accepting the CE Mark. The T2Bact... 
Printer Friendly Version
06/19/17T2 Biosystems Chief Scientific Officer Tom Lowery to Present at BIO 2017 Convention
Panel to Discuss Use of Novel Diagnostic Technologies to Improve Patient Care and Aid in Management of Antimicrobials LEXINGTON, Mass., June 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that its chief scientific officer, Tom Lowery, Ph.D. is scheduled to present at the 2017 BIO International Convention in San Diego, CA as part of a session titled “Using Novel D... 
Printer Friendly Version
06/08/17T2 Biosystems to Present at the 2017 Marcum Microcap Conference
LEXINGTON, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, and Darlene Deptula-Hicks, SVP and chief financial officer, are scheduled to attend and present at the 2017 Marcum Microcap Conference. The conference is being held June 15-16, 2017 at the Grand Hyatt Hotel in New York City. Manageme... 
Printer Friendly Version
06/07/17T2 Biosystems Announces New T2Sepsis Solution™ Clinical and Economic Results Presented by Leading Experts at ASM Microbe 2017 Conference
Clinical Experts Discuss T2BacteriaTM Early Experience and Potential Emergency Department Applications T2Candida® Panel Users Present Compelling Rationale for Adoption, Implementation Process, and the Positive Clinical and Economic Results LEXINGTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced new data on the company’s T2Sepsis Solution, which i... 
Printer Friendly Version
06/01/17Study Published in the Journal of Clinical Microbiology Highlights Detection of Lyme Disease-Causing Bacteria in Blood Using T2 Biosystems’ T2MR® Technology
Data show strong evidence that Lyme disease-causing bacteria exist in blood and that T2MR has superior sensitivity to conventional PCR methods for direct detection in blood. LEXINGTON, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that a new study, “T2 Magnetic Resonance-based Direct Detection of Three Lyme Disease-Related Borrelia Species in Whole B... 
Printer Friendly Version
05/30/17T2 Biosystems to Present at the Jefferies 2017 Global Healthcare Conference
LEXINGTON, Mass., May 30, 2017 (GLOBE NEWSWIRE) --  T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, and Darlene Deptula-Hicks, SVP and chief financial officer are scheduled to attend and present at the Jefferies 2017 Global Healthcare Conference. The conference is being held June 6-9, 2017 at the Grand Hyatt Hotel in New York City. ... 
Printer Friendly Version
05/24/17T2 Biosystems Announces Presentations at ASM Microbe 2017 Conference
LEXINGTON, Mass., May 24, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced two Industry & Science Showcases during the American Society for Microbiology (ASM) Microbe 2017 Conference in New Orleans, LA., June 1-5. Additionally, there will be several Sessions and Poster Presentations focused on the positive impact of the T2 Magnetic Resonance (T2MR®) technology by T2... 
Printer Friendly Version
05/19/17Henry Ford Health System to Present Webinar on Positive Clinical Impact of T2 Biosystems’ T2Candida® Panel
Webinar to be hosted by Dr. George Alangaden, Senior Staff Physician Director, Henry Ford Hospital LEXINGTON, Mass., May 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc., (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, announced today the company, in collaboration with LabRoots, will host a webinar on May 22, 2017, beginning at 10:00 a.m. PT/1:00 p.m. ET. The webinar will be hosted... 
Printer Friendly Version
05/02/17T2 Biosystems Reports First Quarter 2017 Results and Corporate Update
LEXINGTON, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced operating highlights and financial results for the first quarter ended March 31, 2017. Recent Operational and First Quarter Performance Highlights: Secured commitments from new hospitals in the U.S. and Europe that will provide access to an estimated 30,000 additional patients annually considered to be at high risk for sepsis infections. Secured contracts with 2 hospitals: 1 in the U... 
Printer Friendly Version
05/01/17T2 Biosystems Names Darlene Deptula-Hicks as Chief Financial Officer
LEXINGTON, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that Darlene Deptula-Hicks has been named senior vice president and chief financial officer. Ms. Deptula-Hicks is an accomplished financial executive in the life sciences and medical technology industries and has nearly 30 years’ experience leading financial operations for both public and private companies. She brings a proven track record in financial strategy, capital raising, M&A, pro... 
Printer Friendly Version
04/24/17T2 Biosystems Announces 2017 First Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2017 first quarter financial and operational results after the market closes on Tuesday, May 2, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, May 2, 2017, to discuss the financial results and other business developments. Interested parties may access the live call v... 
Printer Friendly Version
04/19/17T2 Biosystems to Host Symposium at 27th European Congress of Clinical Microbiology and Infectious Diseases
Speakers to review clinical and economic benefits of direct-from-whole-blood identification of sepsis pathogens LEXINGTON, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that the company will be hosting a special symposium highlighting the clinical and economic benefits of testing with the T2Candida® Panel and previewing the performance of the T2Bacteria™ Panel at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) ... 
Printer Friendly Version
03/28/17T2 Biosystems to Present at the Needham Healthcare Conference
LEXINGTON, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, is scheduled to attend and present at the Needham Healthcare Conference on Wednesday, April 5, 2017 at 11:20am ET at the Westin New York Grand Central Hotel in New York City. A live, listen-only webcast of the presentation may be accessed by visiting the Events & Presentations section of the Company’s website at www.t2biosyste... 
Printer Friendly Version
02/13/17T2 Biosystems Reports Fourth Quarter and Full-Year 2016 Results
LEXINGTON, Mass., Feb. 13, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, today announced operating highlights and financial results for the fourth quarter and year ended December 31, 2016. Recent Operational and Fourth Quarter Performance Highlights: Secured commitments in the fourth quarter that will provide access to an estimated... 
Printer Friendly Version
02/06/17T2 Biosystems to Present at the Leerink Global Healthcare Conference
LEXINGTON, Mass., Feb. 06, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, and Shawn Lynch, chief financial officer, are scheduled to attend and present at the Leerink Global Healthcare Conference on Wednesday, February 15, 2017 at 3:30pm ET at the Lotte New York Palace in New York City. A live, listen-only webcast of the presentation may be accessed by visiting the Events & Presentations section of t... 
Printer Friendly Version
02/03/17T2 Biosystems Announces 2016 Fourth Quarter and Full-Year Results Release and Conference Call Date
LEXINGTON, Mass., Feb. 03, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2016 fourth quarter and full-year financial results after the market closes on Monday, February 13, 2017.  In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, February 13, 2017, to discuss the financial results and other business developments. Interested parties may access the li... 
Printer Friendly Version
01/30/17Study Published in the American Journal of Clinical Pathology Highlights Rapid Detection of Platelet Function Using T2MR® Technology
Study Shows T2MR’s Sensitive Detection of Platelet Function at Similar or Lower Platelet Counts than Traditional Tests  Paper Provides Novel Insight Into Platelet Biology Not Evident Using Plasma-Based Platelet Aggregation Tests LEXINGTON, Mass., Jan. 30, 2017 (GLOBE NEWSWIRE) --  T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that a new study, “Rapid evaluation of platelet function with T2 magnetic resonanc... 
Printer Friendly Version
01/25/17T2 Biosystems to Host Webinar on the Vital Role of Transformative Diagnostics in Optimizing Antimicrobial Stewardship
Webinar to be hosted by Dr. Michael A. Pfaller, Chief Medical Officer LEXINGTON, Mass., Jan. 25, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, announced today that the company, in collaboration with LabRoots, will host a webinar on January 31, 2017 beginning at 10:00 a.m. PT/1:00 p.m. ET. The webinar will examine the critical role of r... 
Printer Friendly Version
01/09/17T2 Biosystems Reports Preliminary Fourth Quarter Results and Operational Progress
-- On Track to Meet or Exceed Commercial Guidance and Regulatory Timelines -- LEXINGTON, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, today announced preliminary results for its 2016 fourth quarter. Fourth Quarter Preliminary Performance and Recent Operational Highlights: Secured commitments in the fourth quarter ... 
Printer Friendly Version
01/05/17T2 Biosystems, Inc. Announces $50M Credit Facility
-- Retiring Former Debt Facility; Significantly Decreases Near-Term Cash Needs -- LEXINGTON, Mass., Jan. 05, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products that improve patient health and deliver a strong economic return to healthcare institutions, today announced that it has entered into a $50 million debt facility agreement with CRG LP. The new facility consists of an initial draw of $40 million and the ability to borrow an ad... 
Printer Friendly Version